SubHero Banner

Kisqali® (ribociclib), Kisqali Femara® Co-Pack – Expanded indication

On December 10, 2021, the FDA approved Novartis’ Kisqali (ribociclib), for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced or metastatic breast cancer in combination with:

  • An aromatase inhibitor as initial endocrine-based therapy; or
  • Fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men

Download PDF